Director, Yale MMPC; Director, Yale MMPC Metabolic Phenotyping Core
Yale MMPC Phenotyping Core
The Yale MMPC Phenotyping Core empowers Yale MMPC clients with access to unique metabolic phenotyping services that provides them with the means to characterize the metabolic changes in their particular mouse models of complex metabolic disease using established state-of-the-art methodology.
It is anticipated that the results generated by the Yale MMPC will lead to a better understanding of the pathophysiology of diabetes and obesity and their related metabolic complications and lead to new therapies. Ultimately, the insights generated from in vivo metabolic phenotyping in mouse models will facilitate the development of precision medicine approaches targeting metabolic pathophysiology and its downstream complications.
The Yale MMPC Phenotyping Core structure is comprised of four subcores.
Core Leadership
Associate Director of the Yale MMPC Metabolic Phenotying Core, Director of the Vibrant Program
Metabolic Imaging Sub-Core
The aim of the Metabolic Imaging Sub-Core is to offer investigators the ability to assess whole-body fat and lean body mass by 1 H MRS/MRI at 11.7T, and 8.4T as well as several new and exciting PET imaging modalities for their mice.
Sub-Core Leadership
Islet Cell Biology Sub-Core
The aim of Islet Cell Biology Sub-Core is to offer researchers advanced techniques to assess insulin secretion and stable isotope-traced metabolic flux rates in isolated islets.
Details for this sub-core can be found on our website or on the university core website.
Sub-Core Leadership
Thermometabolism Sub-Core
The Thermometabolism Sub-Core will perform comprehensive respirometry and behavioral analyses in awake mice at a range of temperatures from 4-30°C.
Sub-Core Leadership
Functional Cardiac Metabolism Sub-Core
The Functional Cardiac Metabolism Sub-Core will use state-of-the-art surgical models of cardiac pathophysiology combined with isotope tracer analysis of cardiac substrate metabolism to facilitate studies to understand how in vivo atrial and ventricular substrate metabolism affects outcomes under conditions of cardiac pathophysiology (diabetic heart disease, heart failure, atrial fibrillation).